Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery

Gelteq Limited, a biotechnology innovator in ingestible gel delivery solutions, recently completed its initial public offering (IPO), raising gross proceeds of $5.2 million. Priced at $4.0 per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024.

Gelteq centers its technology on a proprietary, customizable gel platform designed for precise drug delivery, supporting prescription drugs, nutraceuticals, pet care and sports supplements.

The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience.

Gelteq’s formulations enable the delivery of various active ingredients like branched-chain amino acids, protein, caffeine and essential minerals, opening applications in sports performance, nutrition and therapeutic use.

The gel’s formulation tackles common challenges in medication compliance by improving taste, reducing choking risk and enabling easier swallowing, especially for individuals with dysphagia or populations with specific dietary or swallowing needs, such as children and seniors.

Additionally, Gelteq’s technology adjusts release profiles across the gastrointestinal tract, tailoring absorption rates and targeting specific sites based on active ingredients.

XTALKS WEBINAR: Transitioning Drug Products or Vaccines into a Prefilled Blow-Fill-Seal Drug Delivery Device

Live and On-Demand: Wednesday, November 13, 2024, at 1pm EST (10am PST)

Register for this free webinar to learn how Blow-Fill-Seal (BFS) advanced aseptic technology offers liquid drug products and vaccines significant advantages over traditional glass vials, such as cost efficiency, transportability and improved environmental sustainability.

To address growing demand, Gelteq is expanding production capacity with a Good Manufacturing Practice (GMP)-certified facility, aiming for scalable, reliable output by 2025.

In the pharmaceutical segment, Gelteq advances its lead product — a gel-based pain management therapy — through the US Food and Drug Administration (FDA)’s 505(b)(2) pathway. This regulatory strategy leverages bioequivalence studies to expedite approval, positioning Gelteq’s gel as an alternative to traditional oral delivery forms. The platform’s versatility supports multi-ingredient and larger dosage capacity, accommodating both lipid and non-lipid combinations, and delivers effective, easy-to-administer drug formulations.

With an expanding patent portfolio and partnerships in human and animal health, Gelteq promotes therapeutic efficacy and patient adherence across diverse health markets.

Across the industry, recent innovations in drug delivery signal a creative shift towards ease of administration and expanded treatment options.

Companies like Mallinckrodt, with its SelfJect injector for chronic and autoimmune conditions, and Evofem Biosciences, with its hormone-free Phexxi contraceptive gel, are developing solutions that simplify and improve medication use for patients with specific needs. Similarly, Viome’s ingestible MyBiotics Toothpaste & Gel leverages oral microbiome data to support systemic health, showcasing a new wave of treatments connecting localized delivery with broader health impacts.

While some other competitors are focused on transdermal patches, oral films and chewing gum for drug delivery, Gelteq’s approach offers a new, distinctive alternative with its stable gel matrix.